

Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. *Blood Adv.* 2023;7(18):5603–5607.

Page 5604: under “Results,” in the sentence that begins “Unlike non-CRS indications that received a median of 3.5 doses of emapalumab,” “supplemental Table 2” should read “supplemental Table 1.”

---

<https://doi.org/10.1182/bloodadvances.2023011828>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](#), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.